Fredrik Frejd

Company: Affibody

Job title: Chief Scientific Officer

Seminars:

A Theranostic Approach to HER2 Radio-ADC Precision Medicine Using Affibody Scaffold Technology 2:00 pm

• HER2-imaging is an attractive tool for characterization of tumor uptake • High contrast tumor targeting ability demonstrated in patients with metastatic breast cancer • Lack of tumor uptake in HER2 IHC+ tumor predicted lack of response to conventional HER2 treatment • Imaging scaffold has been engineered to allow for molecular radiotherapy • Preclinical molecular…Read more

day: Day One